EU Pharma Revision: Legislators Prepare For Long-Haul Debate
Executive Summary
The European Parliament and the Council of the EU are preparing their positions on the planned overhaul of the EU medicines legislation ahead of discussions that are expected to take two to three years.
You may also be interested in...
EMA: Five-Year Regulatory Network Strategy Still ‘Valid And Relevant’ At Midway Point
A report by the European Medicines Agency outlines the progress that has been made so far in delivering on the key pillars of its five-year network strategy, proposed in 2020, and lists areas where work is ongoing.
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.
EU Pharma Revision Proposals Still Awaiting Start Of Legislative Debate
The texts of the proposals cannot be formally presented to the European Parliament until they have been translated into all of the EU’s official languages.